Smoking, South Korea
Smoking, South Korea @beautysouthkorea_com: Quit/stop smoking with the medication ChampixŽ. Smoking cessation clinic, South Korea. Private and confidential services. Definitions, references, and latest news.
Quit smoking with the medication Champix®. Revolutionary new way to stop smoking at our smoking cessation clinic. Get away from the harmful effects of smoking, without feeling the effects of withdrawal!
Come to sunny Singapore to have your testing and treatment. Singapore Ministry of Health registered general practice (GP) clinic:
| SHIM CLINIC|
168 Bedok South Avenue 3 #01-473
Tel: (+65) 6100 7446
Fax: (+65) 6449 7446
24hr Answering Tel: (+65) 6333 5550
Web: Smoking, South Korea
| Opening Hours |
Monday to Friday: 9 am to 3 pm, 7 pm to 11 pm
Saturday & Sunday: 7 pm to 11 pm
Public Holidays: Closed
Last registration: half hour before closing time.
Walk-in clinic. Appointments not required.
Bring NRIC, Work Pass or Passport for registration.
Fiftyâtwoâweek continuous abstinence rates of smokers being treated with varenicline versus nicotine replacement therapy
Mon, 13 May 2013 04:00:00 +0100 | Addiction
ConclusionsSmokers in the same behavioural support programme who use varenicline appear to have a greater probability of achieving longâterm abstinence than those using their choice of nicotine replacement therapy options, even after adjusting for potentially confounding smoker characteristics. (Source: Addiction)
Dissociable effect of acute varenicline on tonic versus cue-provoked craving in non-treatment-motivated heavy smokers
Sun, 05 May 2013 11:11:37 +0100 | Drug and Alcohol Dependence
Conclusions: Acute varenicline selectively attenuates tonic but not cue-provoked craving. This dissociation provides insight into the specific psychological processes that might mediate the effectiveness of varenicline, and highlights cue-provoked craving as a discrete target for advancing smoking cessation pharmacotherapy. (Source: Drug and Alcohol Dependence)
Commentary on âThe Effectiveness of Varenicline Medication Guide for Conveying Safety Information to Patients: a REMS Assessment Surveyâ by Enger et al.
Wed, 01 May 2013 04:00:00 +0100 | Pharmacoepidemiology and Drug Safety
(Source: Pharmacoepidemiology and Drug Safety)
Internet Versus In-Person Counseling for Patients Taking Varenicline for Smoking Cessation
Sun, 14 Apr 2013 19:10:49 +0100 | Military Medicine
(Source: Military Medicine)
Smoking Termination Opportunity for inPatients (STOP): superiority of a course of varenicline tartrate plus counselling over counselling alone for smoking cessation: a 12-month randomised controlled trial for inpatients
Fri, 12 Apr 2013 04:00:00 +0100 | Thorax
Use of varenicline versus bupropion and risk of psychiatric adverse events
Thu, 04 Apr 2013 04:00:00 +0100 | Addiction
ConclusionsIn Denmark, the risk of psychiatric adverse events diagnosed during an emergency department visit or inâpatient admission was not significantly higher with varenicline use compared with bupropion. (Source: Addiction)
Varenicline May Have Edge in Helping Smokers QuitVarenicline May Have Edge in Helping Smokers Quit
Mon, 01 Apr 2013 16:00:00 +0100 | Medscape Medical News Headlines
Smokers who get counseling to help them quit do better if they also get medication, researchers say. Reuters Health Information (Source: Medscape Medical News Headlines)
Stop-Smoking Drugs Not Equal in Real Life (CME/CE)
Thu, 28 Mar 2013 01:13:07 +0100 | MedPage Today Psychiatry
(MedPage Today) -- Varenicline (Chantix) may hold some longer-term advantages for smoking cessation compared with bupropion (Zyban, others), according to a community-based trial. (Source: MedPage Today Psychiatry)
Antismoking and potential antipsychotic effects of varenicline in subjects with schizophrenia or schizoaffective disorder: A double-blind placebo and bupropion-controlled study
Mon, 18 Mar 2013 04:00:00 +0100 | Schizophrenia Research
An increased rate of smoking among subjects with schizophrenia contributes to multiple negative health effects including higher rates of coronary heart disease, hypertension, respiratory disease and lung cancer than the general population (). Studies of nicotine cessation or reduction in schizophrenia have focused on a limited armamentarium of pharmacologic agents showing modest effects. Varenicline is a recent smoking cessation agent with potent partial agonism of the Îą4Î˛2 and full agonism of the Îą7 nicotinic acetylcholine receptor; it may also activate the Î˛4 nicotinic acetylcholine receptor (). Despite early reports of varenicline's exacerbation of psychiatric symptoms () leading to FDA issuance of black box warning, several recent studies provide evidence for its safety and effecti...
Pharmacotherapy for smoking cessation: Pharmacological principles and clinical practice
Fri, 15 Mar 2013 04:00:00 +0100 | British Journal of Clinical Pharmacology